跳至主要内容
临床试验/NCT01920295
NCT01920295已完成不适用

Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation as First-line Therapy

Yuksek Ihtisas Hospital2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
2
主要终点
Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)

研究概览

简要总结

Cryoballoon ablation of paroxysmal atrial fibrillation can be used as first-line therapy compared to second choice after failed medical therapy

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • paroxysmal atrial fibrillation, symptomatic

排除标准

  • atrial fibrillation other than PAF, asymptomatic, previous AF ablation

结局指标

主要结局

Recurrent atrial fibrillation, atrial flutter and atrial tachycardia (composite)

时间窗: 9 months from the procedure

At prespecified interval of 9th month from the index procedure occurence of Recurrent atrial fibrillation, atrial flutter and atrial tachycardia ( Number of Participants with Recurrent atrial fibrillation, atrial flutter and atrial tachycardia )was assessed using ambulatory holter ECG monitoring

次要结局

未报告次要终点

研究者

发起方
Yuksek Ihtisas Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Serkan Cay

Associate Professor

Yuksek Ihtisas Hospital

研究点 (2)

Loading locations...

相似试验